Medtronic plc (NYSE: MDT) is sitting at a fascinating crossroads in mid-2026. Currently trading near $78.60, the medical technology powerhouse is priced nearly 40% below its 2021 record highs, offering a highly compelling valuation. For long-term investors, this decline represents a potential opportunity to buy a world-class dividend growth stock at a steep discount. However, price drops alone do not make a stock a buy. To understand the true potential of mdt stock, one must look closely at its financial health, dividend safety, and the major structural changes taking place within the company.

With the company scheduled to report its fourth-quarter and full fiscal year 2026 earnings on June 3, 2026, and a major corporate catalyst underway—the initial public offering (IPO) and subsequent separation of its Diabetes business under the MiniMed Group brand—investors are asking: Is mdt stock a screaming buy, a stable hold, or a value trap? In this deep-dive analysis, we will explore Medtronic's financials, its emerging high-margin growth drivers, its structural reorganization, and the risks you must weigh before adding it to your portfolio.

The MiniMed IPO & Restructuring: A Catalyst to Unlock Shareholder Value

For years, one of the primary criticisms of Medtronic has been its sprawling, complex corporate structure. Over decades of acquisitions, the medical device giant became incredibly bloated, which slowed down the product pipeline and created operational inefficiencies. However, leadership under CEO Geoff Martha has committed to aggressive portfolio management, and we are now seeing the fruits of that strategy.

In May 2025, Medtronic announced its intention to separate its multi-billion-dollar Diabetes business into an independent, publicly traded entity. Fast forward to February 24, 2026, and the company officially launched the IPO roadshow for this new entity, named MiniMed Group, Inc. The IPO, listing on the Nasdaq under the ticker symbol MMED, is offering 28 million shares of common stock with an expected price range of $25.00 to $28.00 per share. Medtronic will initially retain a massive 90.03% stake in the business, with plans for a full split-off or spin-off to existing shareholders down the road.

This separation is a major structural catalyst for several reasons:

• Strategic Alignment: The diabetes care market is highly consumer-oriented. Continuous glucose monitors (CGMs) and automated insulin delivery systems—such as the highly regarded MiniMed 780G—are marketed directly to patients. This direct-to-consumer (D2C) dynamic is fundamentally different from Medtronic's core hospital-centric business model (B2B). Separating the two allows both management teams to focus on their respective competencies.
• Unlocking Valuation: Standalone diabetes technology companies like Dexcom and Tandem historically trade at much higher valuation multiples than diversified medical conglomerates. By spinning off MiniMed, Medtronic is giving the market a pure-play diabetes stock that can command a premium, unlocking hidden value for mdt stock shareholders.
• Capital Allocation: Proceeds from the IPO will be utilized to pay down intercompany debt owed to Medtronic and fund capital-intensive research and development. This permits the remaining Medtronic company to focus on its highest-margin business segments.

This strategic restructuring stands in stark contrast to Medtronic's 2024 decision regarding its Patient Monitoring and Respiratory Interventions (PMRI) division. Initially earmarked for a spinoff in late 2022, Medtronic called off the PMRI separation in February 2024 after realizing that restructuring the business internally made more financial sense. The company merged those segments into a single unit called Acute Care and Monitoring (ACM) while systematically exiting the unprofitable ventilator market. This willingness to pivot shows that management is disciplined, analytical, and highly focused on maximizing margins rather than simply rushing to divest assets.

Moving the Needle: Medtronic's High-Margin Growth Engines

With the diabetes segment being spun off, where will Medtronic's future growth come from? The company is actively shifting its focus to high-margin, high-growth clinical areas where it enjoys deep-seated competitive advantages.

1. Pulsed Field Ablation (PFA) & Cardiac Ablation Solutions

One of the most exciting segments within Medtronic's portfolio is its Cardiovascular division. In the third quarter of fiscal year 2026 (reported on February 17, 2026), Medtronic's Cardiac Ablation Solutions business experienced a staggering 70% to 80% surge following the rapid expansion of its pulsed field ablation technologies. PFA is a revolutionary method of treating atrial fibrillation (AFib) that uses short, high-voltage electrical fields to destroy problematic heart tissue rather than relying on extreme heat or cold (thermal ablation). Because PFA selectively targets cardiac tissue while preserving surrounding structures like the esophagus and phrenic nerve, it is safer, faster, and is rapidly becoming the gold standard in electrophysiology. Medtronic is leading this multi-billion-dollar market expansion.

2. The Hugo Surgical Robot

Minimally invasive surgery is the future, and robotic-assisted surgery (RAS) is the crown jewel of this sector. While Intuitive Surgical's da Vinci system has enjoyed a near-monopoly for years, Medtronic's Hugo RAS system is gaining meaningful traction worldwide. Ramping up sales of the Hugo surgical robot is a major multi-year narrative for Medtronic. Backed by the company's vast global distribution network, clinical training centers, and existing relationships with hospital purchasing managers, Hugo is uniquely positioned to capture market share in a space where global clinical penetration remains remarkably low.

3. Chronic Disease Innovations

Beyond ablation and robotics, Medtronic continues to innovate in high-impact chronic conditions. The Symplicity Spyral system is a renal denervation technology designed to treat severe, uncontrolled hypertension by targeting overactive nerves near the kidneys. Additionally, in neurosurgery, the Stealth AXiS system integrates advanced navigation and imaging to improve precision during complex spinal and cranial operations. These are multi-year secular tailwinds that will support Medtronic's revenue long after the MiniMed separation is complete.

Income and Value: A Dividend King in the Making

For dividend growth investors and value-oriented contrarians, the primary appeal of mdt stock lies in its bulletproof dividend history and historically low valuation.

Medtronic currently boasts 48 consecutive years of annual dividend increases. This remarkable track record means the company is just two years away from reaching the prestigious "Dividend King" status (50 consecutive years). Very few corporations in the world possess the operational resilience required to raise dividends through stagflation, global recessions, tax reforms, and a global pandemic. It is a testament to the highly defensive, cash-generative nature of the medical device industry.

At a current stock price of ~$78.60, Medtronic offers a dividend yield of approximately 3.7%. Historically, Medtronic's yield has hovered between 1.5% and 2.5%, making the current yield one of the highest in the company’s history.

Let's evaluate the fundamental valuation of mdt stock compared to its historical averages:

With free cash flow sitting at an impressive $4.07 billion, Medtronic has more than enough liquidity to easily support its capital expenditures, research and development, and its $2.75-per-share annualized dividend payout. For income-focused investors, this high yield combined with near-certain dividend growth offers a highly defensive, equity-based income stream.

Risks and Hurdles: Why Has MDT Underperformed, and Can It Recover?

To write an honest assessment of mdt stock, we must address the elephant in the room: why has this stock significantly underperformed the broader S&P 500 over the past five years? While the S&P 500 has set consecutive all-time highs, Medtronic remains stuck in a multi-year consolidation pattern. There are several clear reasons for this underperformance:

• Operational Inefficiencies & Margin Pressure: Over the years, Medtronic's margins have compressed due to rising input costs, supply chain bottlenecks, and complex logistics. The company has struggled with structural bloat, making it slower to pivot compared to nimbler, pure-play medical device competitors.
• Intense Competition: Medtronic is not innovating in a vacuum. In the cardiac ablation space, it faces stiff competition from Boston Scientific and Johnson & Johnson. In surgical robotics, Intuitive Surgical maintains a massive head start with its installed base of over 11,000 da Vinci systems globally. In the diabetes market (prior to the spinoff), Dexcom and Abbott have historically captured market share with more seamless CGM-pump integrations.
• Tariff and Inflationary Headwinds: As a global medical technology manufacturer with production facilities spread across multiple continents, Medtronic is highly sensitive to import/export tariffs, global trade tensions, and localized inflationary pressures. These macro factors have acted as a persistent drag on its bottom-line growth over the past few years.
• Restructuring and Execution Risk: Spinoffs and structural realignments are expensive and complex. De-consolidating a business unit as large as MiniMed requires significant investment, legal fees, and operational adjustments. If the separation of the diabetes business experiences delays or fails to achieve the expected financial synergies, it could temporarily weigh on Medtronic's earnings power.

Wall Street Consensus: Price Targets and Future Outlook for MDT Stock

Despite the historical underperformance, institutional sentiment surrounding Medtronic is turning increasingly bullish in mid-2026. Analysts are recognizing that the company is actively trimming its underperforming segments and doubling down on its highest-margin clinical growth drivers.

According to consensus data from Wall Street analysts covering the stock:

• Average 12-Month Price Target: $106.45
• Median Analyst Target: $110.00
• Highest Price Target: $120.00
• Lowest Price Target: $84.00
• Implied Upside: Based on the current trading price of $78.60, the average price target implies an outstanding 35.33% to 40% upside potential over the next twelve months.

Out of 27 analysts actively covering the stock, the consensus rating is a "Moderate Buy" to "Strong Buy," with a marked shift in sentiment following the company's strong Q2 and Q3 fiscal year 2026 earnings beats. Investors should keep a close eye on the upcoming June 3, 2026 earnings report. If Medtronic beat analyst expectations for Q4 FY26 and raises its fiscal year 2027 guidance, it could be the exact spark needed to initiate a sustained breakout for mdt stock.

Medtronic (MDT) Stock: Frequently Asked Questions

When is Medtronic's next earnings report date?

Medtronic is scheduled to report its financial results for the fourth quarter and full fiscal year 2026 on Wednesday, June 3, 2026, before the market opens. Management will host a video webcast at 6:45 a.m. Central Time (CT) to discuss the results, update guidance, and provide commentary on the progression of the MiniMed IPO.

Is Medtronic a Dividend King?

Not yet, but it is incredibly close. Medtronic has raised its dividend for 48 consecutive years, making it a prominent member of the S&P 500 Dividend Aristocrats index. It needs just two more years of consecutive dividend growth to reach the coveted 50-year milestone and officially become a Dividend King.

How will the MiniMed IPO affect existing Medtronic shareholders?

The separation of the Diabetes business under the MiniMed Group name (MMED) is structured to benefit current Medtronic shareholders. Medtronic plans to execute a multi-step capital markets transaction, starting with an IPO of a minority stake (approximately 10%) to raise capital and establish a public market value. Afterward, Medtronic expects to distribute its remaining ~90% stake to its existing shareholders via a tax-free split-off or spin-off, meaning MDT shareholders would receive shares of the new standalone diabetes company.

Is MDT stock considered undervalued?

Yes, by almost every traditional valuation metric. Trading at a forward P/E of just 14.22x compared to its five-year average of over 20x, mdt stock is priced at a historically cheap valuation. Additionally, its dividend yield of 3.7% is near historic highs, suggesting the stock has reached a deep value floor.

The Bottom Line: Is MDT Stock a Buy Right Now?

Medtronic plc represents a textbook dividend-growth turnaround story. The company is actively shedding its reputation as a slow-moving medical conglomerate through bold restructuring. By taking its high-growth but consumer-oriented Diabetes business public via the MiniMed IPO, Medtronic is streamlining its operations to focus on high-margin cardiovascular technologies, spine innovations, and surgical robotics.

For conservative income investors, mdt stock is a highly attractive buy right now. It offers a defensive, market-beating 3.7% dividend yield, backed by nearly half a century of steady dividend increases. At a forward P/E of just 14.2x, the downside risk from these levels appears exceptionally well-cushioned.

For growth and value investors, the stock offers a massive margin of safety alongside a clear path to double-digit returns through multiple expansion and portfolio optimization. With Wall Street predicting a 35% to 40% upside to an average target price of over $106, buying mdt stock ahead of its crucial June 3, 2026 earnings release could prove to be a highly rewarding move.